Corporate
News release
TopTOKYO, JAPAN – June 27, 2025 – Terumo Corporation (TSE: 4543) today announced that it has initiated liquidation proceedings for Quirem Medical B.V., its wholly owned subsidiary in the Netherlands. Quirem develops and manufactures radiation-emitting beads used in interventional oncology (catheter-based liver cancer treatment).
Terumo acquired Quirem in 2020 and has since marketed Quirem’s radiation-emitting beads in the European market. Although the company sought to expand Quirem’s global footprint, challenges in expanding into markets outside Europe mainly due to regulatory differences, along with intensifying competition, have led to a deterioration in the business environment, making it difficult to achieve the originally anticipated growth for this business.
In light of these circumstances, Terumo ceased sales of the radiation-emitting beads, and has engaged in discussions with Quirem’s Works Council regarding the closure of operations since May 2025. With these discussions now concluded, Terumo has formally initiated liquidation process. The liquidation is expected to be completed during the third quarter of fiscal 2025.
While Terumo will exit the radiation-emitting beads business following the liquidation of Quirem, the company will continue to position interventional oncology as a strategic growth area. Terumo remains committed to delivering innovative products in areas such as microcatheters, embolic beads, drug-eluting beads, and resorbable drug-eluting beads, to support better outcomes and offer a broader range of treatment options for liver cancer patients.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.